-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GlmhheDFhbgcGu3ONyu/+WGLeb4jr4eyn1fUJFDnkNek+iKBarc4zCYoruCWnZC5 8Zt1u8z8zjcQXK2AIOBjKQ== 0001209191-07-016817.txt : 20070309 0001209191-07-016817.hdr.sgml : 20070309 20070309150145 ACCESSION NUMBER: 0001209191-07-016817 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070308 FILED AS OF DATE: 20070309 DATE AS OF CHANGE: 20070309 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SMITH MARK L CENTRAL INDEX KEY: 0001206467 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-52082 FILM NUMBER: 07684098 BUSINESS ADDRESS: BUSINESS PHONE: 5619895800 MAIL ADDRESS: STREET 1: NABI PHARMACEUTICALS STREET 2: 5800 PARK OF COMMERCE BLVD N.W. CITY: BOCA RATON STATE: FL ZIP: 33487 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIDYNE INC CENTRAL INDEX KEY: 0001180145 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841568247 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1450 INFINITE DRIVE CITY: LOUISVILLE STATE: CO ZIP: 80027 BUSINESS PHONE: 303-665-3450 MAIL ADDRESS: STREET 1: 1450 INFINITE DRIVE CITY: LOUISVILLE STATE: CO ZIP: 80027 4 1 bdn44245_bdn4mls.xml MAIN DOCUMENT DESCRIPTION X0202 4 2007-03-08 0001180145 REPLIDYNE INC RDYN 0001206467 SMITH MARK L 1450 INFINITE DRIVE LOUISVILLE CO 80027 0 1 0 0 CFO and Treasurer Stock Option (right to buy) 5.35 2007-03-08 2007-03-08 4 A 0 90000 0 A 2008-03-08 2017-03-08 Common Stock 90000 90000 D Grant to Reporting Person of a stock option under the Issuer's 2006 Equity Incentive Plan. The option vests over a four year period, with 25% of such option vesting on the one year anniversary of the Vesting Commencement Date and the remaining 75% of such option vesting in equal monthly installments over the next 36 months. The option expires ten years after the date of grant. /s/ Laura M. Medina, Attorney-in-Fact 2007-03-09 -----END PRIVACY-ENHANCED MESSAGE-----